Table 1.
Characteristics of Study Participants
| Characteristic | PROMOTE (n = 184) | TCC (n = 57) |
|---|---|---|
| At the beginning of the observation period | ||
| Age, y, mean (SD) | 3.4 (1.3) | 0.6 (0.3) |
| Female sex, No. (%) | 92 (49.5) | 28 (49.1) |
| ART naive, No. (%) | 129 (70.1) | 57 (100) |
| WHO stage, No. (%) | ||
| I | 135 (73.4) | 43 (75.4) |
| II | 35 (19.0) | 7 (12.3) |
| III | 3 (1.6) | 7 (12.3) |
| IV | 11 (6.0) | 0 |
| CD4 percentage, median (range) | ||
| ART naive | 16 (2–44) | 21 (2–61) |
| ART experienced | 30 (8–51) | NA |
| Viral load, log10 copies/mL, median (range) | ||
| ART naive | 5.4 (2.6–6.4) | 5.9 (2.8–7.0) |
| ART experienced | All undetectable | NA |
| During follow-up | ||
| Duration of follow-up, y, median (IQR) | 2.1 (1.9–2.7) | 2.2 (1.8–4.3) |
| On ARVs, No. (%) | 184 (100) | 52 (91) |
| Total No. of treatments for malaria | 581 | 367 |
| Malaria treatments per child, median (range) | 1 (0–26) | 2 (0–45) |
| Incidence of malaria per person-year | 1.45 | 2.31 |
Abbreviations: ART, antiretroviral therapy; ARV, antiretroviral; IQR, interquartile range; NA, not applicable; SD, standard deviation; TCC, Tororo Child Cohort; WHO, World Health Organization.